BioCryst Pharmaceuticals (NASDAQ:BCRX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research note published on Tuesday, Benzinga reports. HC Wainwright currently has a $30.00 price target on the biotechnology company’s stock.

Separately, Needham & Company LLC reaffirmed a buy rating and issued a $12.00 price target on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average price target of $14.00.

BioCryst Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ:BCRX opened at $5.26 on Tuesday. The company has a market capitalization of $1.09 billion, a PE ratio of -4.46 and a beta of 1.96. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $8.96. The business’s fifty day simple moving average is $4.90 and its 200-day simple moving average is $5.45.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06. The company had revenue of $92.80 million during the quarter, compared to analysts’ expectations of $85.62 million. During the same quarter last year, the firm earned ($0.28) EPS. BioCryst Pharmaceuticals’s revenue for the quarter was up 34.9% on a year-over-year basis. Research analysts predict that BioCryst Pharmaceuticals will post -0.69 EPS for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Fifth Third Bancorp raised its stake in BioCryst Pharmaceuticals by 17,500.0% in the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 3,500 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 96.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 2,388 shares during the period. Quarry LP purchased a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth about $54,000. Tower Research Capital LLC TRC lifted its holdings in shares of BioCryst Pharmaceuticals by 131.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 5,912 shares during the period. Finally, JGP Global Gestao de Recursos Ltda. purchased a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $64,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.